Risankizumab effectiveness and safety in psoriasis patients who failed other biologics: Real-life case series-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Risankizumab effectiveness and safety in psoriasis patients who failed other biologics: Real-life case series

Published:2021-12-24 Issue: Volume:0 Page:1-6
ISSN:0378-6323
Container-title:Indian Journal of Dermatology, Venereology and Leprology
language:en
Short-container-title:IJDVL

Author:

Dawoud Noha Mohammed,El Badawy Maha Bedair¹,Al Eid Hala Subhi²,Abdel Fattah Moataz M³

Affiliation:

1. Department of Dermatology, Al Hada Armed Forces Hospital, Taif, Saudi Arabia

2. Department of Clinical Pharmacy, Al Hada Armed Forces Hospital, Taif, Saudi Arabia

3. Department of Research Administration, Al Hada Armed Forces Hospital, Taif, Saudi Arabia

Publisher

Scientific Scholar

Subject

Infectious Diseases,Dermatology

Reference12 articles.

1. Risankizumab as a promising therapeutic approach in obese patients;Ruiz-Villaverde;Dermatol Ther,2020

2. Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): A randomised, double-blind, active-comparator-controlled phase 3 trial;Reich;Lancet,2019

3. Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): Results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial;Warren;Br J Dermatol,2021

4. Risankizumab: A pilot study of short-term effectiveness and safety in real clinical practice;Ruiz-Villaverde;Dermatol Ther,2021

5. A multicenter study on effectiveness and safety of risankizumab in psoriasis: An Italian 16-week real-life experience during the COVID-19 pandemic;Hansel;J Eur Acad Dermatol Venereol,2021

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Guselkumab, Risankizumab, and Tildrakizumab in the Management of Psoriasis: A Review of the Real-World Evidence;Clinical, Cosmetic and Investigational Dermatology;2022-08

2. Risankizumab shows faster response in bio naïve than in bio‐experienced psoriatic patients;Journal of the European Academy of Dermatology and Venereology;2022-06-22

3. Risankizumab treatment in psoriasis patients who failed anti‐IL17: A 52‐week real‐life study;Dermatologic Therapy;2022-04-26

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3